Breaking News Instant updates and real-time market news.

MLHR

Herman Miller

$37.86

0.75 (2.02%)

, KBH

KB Home

$23.58

-0.24 (-1.01%)

18:51
06/26/19
06/26
18:51
06/26/19
18:51

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Herman Miller (MLHR), up 12.2%... KB Home (KBH), up 4.4%. ALSO HIGHER: The Peck Company (PECK), up 34.4% after it announced a $17M agreement to construct solar arrays generating 7 MW... Verrica (VRCA), up 10.2% after tis VP-102 achieved positive results on both its primary and secondary endpoints in a Phase 2 open label clinical study. DOWN AFTER EARNINGS: Pier 1 Imports (PIR), down 15.8%... Rite Aid (RAD), down 10.6%. ALSO LOWER: Aclaris (ACRS), down 33.7% after results from a Phase 2 clinical trial of ATI-502 missed its primary and secondary endpoints... Boeing (BA), down 1.3% after Reuters reported tha thte FAA found a "potential risk" that Boeing "must mitigate" in the 737 MAX.

MLHR

Herman Miller

$37.86

0.75 (2.02%)

KBH

KB Home

$23.58

-0.24 (-1.01%)

PECK

Peck

$6.50

0.18 (2.85%)

VRCA

Verrica Pharmaceuticals

$9.44

-0.1 (-1.05%)

PIR

Pier 1 Imports

$8.80

0.14 (1.62%)

RAD

Rite Aid

$7.11

0.26 (3.80%)

ACRS

Aclaris Therapeutics

$4.45

0.06 (1.37%)

BA

Boeing

$375.05

5.68 (1.54%)

  • 26

    Jun

  • 26

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jun

  • 09

    Jul

  • 17

    Jul

  • 24

    Jul

  • 01

    Oct

  • 02

    Oct

MLHR Herman Miller
$37.86

0.75 (2.02%)

05/01/19
SIDC
05/01/19
DOWNGRADE
Target $41
SIDC
Neutral
Herman Miller downgraded to Neutral on valuation at Sidoti
As previously reported, Sidoti analyst Gregory Burns downgraded Herman Miller to Neutral from Buy, citing valuation with the stock now trading near his unchanged price target of $41. Investments in the Consumer segment are driving solid revenue growth, but margin expansion is lagging, said Burns, who acknowledges the potential for upside if the company is able to execute. However, he thinks headwinds will persist, at least in the near-term, he tells investors.
05/01/19
SIDC
05/01/19
DOWNGRADE
SIDC
Neutral
Herman Miller downgraded to Neutral from Buy at Sidoti
KBH KB Home
$23.58

-0.24 (-1.01%)

06/18/19
RAJA
06/18/19
DOWNGRADE
Target $55
RAJA
Market Perform
Lennar downgraded to Market Perform on 'rich' valuation, says Raymond James
Raymond James analyst Buck Horne downgraded Lennar (LEN) to Market Perform from Outperform with a $55 price target ahead of the company's earnings report in a move to highlight his increased near-term caution with the homebuilding sector. In a research note to investors, Horne cites factors including above-average cyclical valuations amid declining earnings estimates across the industry, softening macro-economic data points and indicators of a late-cycle shift, and an analysis of recent MSA-level re-sale market statistics suggesting competitive inventory remains elevated into summer for the downgrade. Horne also downgraded KB Home (KBH) to Underperform from Market Perform.
06/18/19
RAJA
06/18/19
DOWNGRADE
RAJA
Underperform
KB Home downgraded to Underperform from Market Perform at Raymond James
Raymond James analyst Buck Horne downgraded KB Home to to Underperform from Market Perform saying he sees a "rich" valuation ahead of earnings.
06/17/19
BUCK
06/17/19
NO CHANGE
Target $56
BUCK
Buy
Buckingham 'constructive' on Lennar, KB Home ahead of earnings reports
Buckingham analyst Megan McGrath tells investors in a research note that she remains "constructive" on both Lennar (LEN) and KB Home (KBH) ahead of the companies' earnings report next week, saying she expects both companies to continue to point to improvements in demand trends through the quarter and an easing of incentives vs. Q1 levels. The analyst, who maintains a Buy rating and $56 price target on Lennar and a Neutral rating and $27 price target on KB Home, says she currently prefers Lennar's more diverse regional exposure andfaster absorption pace for a one-year outlook to KB Home's high California exposure and higher debt levels.
06/18/19
RAJA
06/18/19
DOWNGRADE
RAJA
Underperform
KB Home downgraded to Underperform on 'rich' valuation at Raymond James
Raymond James analyst Buck Horne downgraded KB Home (KBH) to Underperform from Market Perform ahead of the company's earnings report in a move to highlight his increased near-term caution with the homebuilding sector. In a research note to investors, Horne cites factors including above-average cyclical valuations amid declining earnings estimates across the industry, softening macro-economic data points and indicators of a late-cycle shift, and an analysis of recent MSA-level re-sale market statistics suggesting competitive inventory remains elevated into summer for the downgrade. Horne also downgraded Lennar (LEN) to Market Perform from Outperform.
PECK Peck
$6.50

0.18 (2.85%)

VRCA Verrica Pharmaceuticals
$9.44

-0.1 (-1.05%)

07/10/18
BOFA
07/10/18
INITIATION
Target $26
BOFA
Buy
Verrica Pharmaceuticals initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Jason Gerberry initiated Verrica Pharmaceuticals with a Buy and $26 price target based on primary asset VP-102, for the treatment of molluscum, which is in Phase 3 development. The analyst said the US molluscum market alone has over 1M new patients a year without any FDA approved treatments.
05/15/19
HCWC
05/15/19
NO CHANGE
Target $20
HCWC
Buy
Verrica opportunity in molluscum 'far undervalued," says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat says the recent weakness in shares of Verrica Pharmaceuticals is "unexplained" as the company remains on track for a VP-102 molluscum new drug application filing in the second half of 2019. Only final stability testing and manufacturing are gating factors for the application filing, and final approval in the second half of 2020 is "relatively low risk" given the statistically significant Phase 3 data and the unmet need in the indication, Livnat tells investors in a research note. The analyst remains bullish on Verrica's molluscum opportunity, projecting $400M "peak high-margin" sales in the U.S. He thinks this is "far undervalued in Verrica's current $160M enterprise value." The analyst reiterates a Buy rating on Verrica Pharmaceuticals with a $20 price target.
02/21/19
HCWC
02/21/19
INITIATION
Target $20
HCWC
Buy
Verrica Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat started Verrica Pharmaceuticals with a Buy rating and $20 price target. The analyst's valuation is based solely on Verrica's lead candidate, VP-102, for molluscum, a pediatric viral skin infection. VP-102 has recently demonstrated robust Phase 3 efficacy, says the analyst, who projects a late-2020 launch. He projects $400M peak U.S. sales in molluscum.
02/21/19
02/21/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. At Home Group (HOME) initiated with a Hold at Loop Capital. 2. Harmonic (HLIT) initiated with a Buy at Stifel. 3. Atkore (ATKR) initiated with a Neutral at Credit Suisse. 4. BioTime (BTX) and Verrica Pharmaceuticals (VRCA) were initiated with a Buy at H.C. Wainwright. 5. Aphria (APHA), KushCo Holdings (KSHB), and HEXO Corp (HEXO) were initiated with a Buy at Seaport Global, while Canopy Growth (CGC), Aurora Cannabis (ACB), and Tilray (TLRY) were initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
PIR Pier 1 Imports
$8.80

0.14 (1.62%)

04/24/19
MSCO
04/24/19
NO CHANGE
Target $30
MSCO
Overweight
At Home could double market share, triple sales by 2028, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman said he believes At Home Group (HOME) can drive meaningful share gains with its superior value proposition of the lowest prices, a wide assortment and high levels of in-stock inventory. Over the next ten years, he estimates At Home could double its market share and triple its revenue, highlighting Pier 1 Imports (PIR) as one of "many" potential share donor, stating that his analysis suggests At Home could capture greater than $110M in sales from Pier 1 over the next ten years. Gutman keeps an Overweight rating and $30 price target on At Home shares.
03/21/19
GDHS
03/21/19
NO CHANGE
GDHS
Gordon Haskett shakes up retailer rankings with six upgrades, three downgrades
Gordon Haskett analysts Chuck Grom, John Park and Andrew Minora have recalibrated their ratings in broadline and hardline retail with the Q4 earnings season nearly complete, stating that holiday results were mixed with clear winners and losers and that year-to-date sales have been "extremely choppy." The firm's latest macro/consumer survey results suggest that some optimism has resurfaced and they see a scenario where there is a release of significant pent-up demand for the retail group. Within the context of a portfolio approach to the space, the analysts upgraded Target (TGT), Tractor Supply (TSCO), Dollar Tree (DLTR), BJ's Wholesale (BJ) to Buy from Accumulate, upgraded Wayfair (W) and Floor & Decor (FND) to Accumulate from Hold, and downgrade Nordstrom (JWN) and Sprouts Farmers Market (SFM) to Reduce from Hold. The analysts also downgraded Pier 1 Imports (PIR) to Underperform from Hold.
03/21/19
GDHS
03/21/19
DOWNGRADE
GDHS
Underperform
Pier 1 Imports downgraded to Underperform at Gordon Haskett
01/08/19
GDHS
01/08/19
UPGRADE
GDHS
Hold
Pier 1 Imports upgraded to Hold from Underperform at Gordon Haskett
RAD Rite Aid
$7.11

0.26 (3.80%)

04/25/19
DESJ
04/25/19
INITIATION
DESJ
Buy
Desjardins initiates HEXO Corp, Canopy Growth, Aurora Cannabis with a Buy
Desjardins analyst John Chu initiated HEXO Corp (HEXO), Canopy Growth (CGC), and Aurora Cannabis (ACB) with a Buy rating and respective price targets of C$14, C$74, and C$16.50 as part of a broad research note, saying the "hype" around legalization of adult-use cannabis in Canada remains strong in spite of "underwhelming" early months of sales. The analyst attributes the challenges to ramp-up, logistical and distribution issues, but expects investors to consider the opportunity as a "global" one. Chu believes that "major" consumer packaged goods companies like Constellation (STZ), InBev (BUD), and Altria (MO), as well as retailers like Walgreens (WBA), CVS (CVS), and Rite Aid (RAD) should "help push cannabis and hemp into the mainstream."
04/18/19
04/18/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Morgan Stanley (MS) downgraded to Neutral from Buy at Citi with analyst Keith Horowitz saying Morgan Stanley reported "strong" Q1 results but the shares are fairly valued. 2. Snap (SNAP) downgraded to Negative from Mixed at Vertical Group and to Neutral from Outperform at Wedbush. 3. Rite Aid (RAD) downgraded with a Sell from Neutral at Guggenheim while Walgreens Boots Alliance (WBA) was downgraded with a Neutral from Buy. 4. CF Industries (CF) downgraded to Underperform from Buy at BofA/Merrill with analyst Steve Byrne saying he has spoken with 10 key channel contacts in the Cornbelt and several commented that never in their 30-plus year careers have they seen fertilizer applications this far behind, mainly due to the weather. 5. FMC Corporation (FMC) downgraded to Sector Perform from Outperform at RBC Capital with analyst Arun Viswanathan citing the "uncertainty of Rynaxypyr and Cyazypyr patent expiration" as well as the reduced multiple from the recent lithium separation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/17/19
GUGG
04/17/19
DOWNGRADE
GUGG
Sell
Rite Aid assumed with a Sell from Neutral at Guggenheim
04/17/19
GUGG
04/17/19
DOWNGRADE
GUGG
Sell
Rite Aid assumed with a Sell from Neutral at Guggenheim
Guggenheim analyst Glen Santangelo assumed coverage of Rite Aid and downgraded the shares to Sell from the firm's Neutral rating under analyst John Heinbockel. Santangelo also lowered the price target fro Rite Aid to 35c per share, down from 45c per share. The analyst believes Rite Aid's "significant debt burden" and "high leverage will continue to limit Rite Aid's ability to work through its structural and competitive issues."
ACRS Aclaris Therapeutics
$4.45

0.06 (1.37%)

06/12/19
CANT
06/12/19
NO CHANGE
Target $24
CANT
Overweight
Aclaris Therapeutics price target lowered to $24 from $50 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen lowered her price target for Aclaris Therapeutics to $24 from $50, driven by multiple contraction, given increasing headwinds from macro factors. Chen sees key potential risks, including launch and/or pipeline failures for A-101 and the earlier-stage pipeline that could delay the company's time to achieve profitability. Additionally, the analyst notes that Aclaris faces competition from a number of large and small companies, some of which have greater financial, R&D, production, and other resources than Aclaris. Chen has an Overweight rating on the shares.
12/31/18
CANT
12/31/18
NO CHANGE
Target $50
CANT
Overweight
Aclaris market cap should be much greater than $300M, says Cantor Fitzgerald
With two commercial drugs, Rhofade and Eskata, and up to six positive data readouts in 2019, Aclaris Therapeutics' market capitalization should be much greater than $300M, Cantor Fitzgerald analyst Louise Chen tells investors in a research note titled "Don't Make Me Tell You Until I'm Red In The Face." The analyst believes Rhofade's soft re-launch, which started on November 1, is gaining traction and that the drug's "positive momentum is not getting the attention that it deserves." Chen previously highlighted Aclaris as one of her top ideas heading into 2019 and she keeps an Overweight rating on the shares with a $50 price target.
05/06/19
05/06/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. PagerDuty (PD) initiated with an Overweight at Piper Jaffray, with a Neutral at BTIG, with an Outperform at William Blair, with an Overweight at JPMorgan, with a Sector Weight at KeyBanc, with an Equal Weight at Morgan Stanley and with a Sector Perform at RBC Capital. 2. Tufin (TUFN) initiated with a Buy at Jefferies, with an Overweight at Piper Jaffray, with a Market Perform at William Blair, with a Hold at Stifel, with an Outperform at Oppenheimer, with an Overweight at JPMorgan and with an Overweight at Barclay. 3. Aclaris Therapeutics (ACRS) initiated with an Outperform at SVB Leerink. 4. Jumia Technologies (JMIA) initiated with a Neutral at Citi and with a Sector Perform at RBC Capital. 5. Omeros (OMER) initiated with an Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/06/19
LEER
05/06/19
INITIATION
Target $13
LEER
Outperform
Aclaris Therapeutics initiated with an Outperform at SVB Leerink
SVB Leerink analyst Pasha Sarraf initiated Aclaris Therapeutics with an Outperform rating and $13 price target.
BA Boeing
$375.05

5.68 (1.54%)

05/28/19
EVER
05/28/19
DOWNGRADE
Target $60
EVER
In Line
Southwest downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst Duane Pfennigwerth downgraded Southwest Airlines (LUV) to In Line from Outperform with a $60 price target, pointing to the negative impact that the grounding of Boeing's (BA) 737 MAX jet has had on the air carrier. In a research note to investors, Pfennigwerth says Southwest's inability to grow is due to its reliance on the 737 MAX, and in return for betting on the MAX as its longer-term growth platform, Southwest has gotten operational "headaches," lost market share and likely short-term impact to its brand when the MAX returns to service. The analyst sees Southwest shares as range bound until the MAX formally returns to service.
05/24/19
MSCO
05/24/19
NO CHANGE
Target $500
MSCO
Overweight
Morgan Stanley keeps Overweight rating on Boeing after 'good enough' FAA meeting
Morgan Stanley analyst Rajeev Lalwani said he views the FAA meeting on May 23 with global regulators on the status of the 737 MAX as supportive of Boeing and "good enough" given that there were no major setbacks in progressing on the return to service of the MAX, there appeared to be a collaborative approach among aviation authorities and a 1-2 month timeline was not ruled out. Lalwani, who thinks the dialogue is shifting more towards when the aircraft can get back into service as opposed to if, said he remains comfortable with his Overweight rating and $500 price target on Boeing shares, especially with the shares down about 20% from their recent highs.
06/18/19
BOFA
06/18/19
NO CHANGE
Target $420
BOFA
Neutral
Boeing 737 MAX rebranding wouldn't fix issues, says BofA/Merrill
BofA/Merrill analyst Ronald Epstein commented on Day 1 of the Paris Air Show, telling investors that "there were more questions than answers" regarding Boeing's 737 MAX. In a research note to investors, Epstein says his team's conversations with suppliers and other industry participants did not provide additional clarity on the certification of the 737 MAX, and says Boeing appears to be using the show as opportunity to explain what has gone wrong with 737 Max program, adding that he is "surprised" that the 737 MAX is in the position that it is. Epstein also notes that a rebranding effort for the 737 MAX would likely not fix the confidence issues facing the MAX, as "A rose by any other name would smell as sweet."
06/11/19
JEFF
06/11/19
NO CHANGE
Target $448
JEFF
Buy
Boeing's May deliveries 'weak' due to 737 MAX grounding, says Jefferies
Boeing delivered 30 commercial aircraft in May vs. 68 a year ago, Jefferies analyst Sheila Kahyaoglu tells investors in a research note, saying that the deliveries were weak given the 737 MAX grounding. The analyst continues to forecast Q2 deliveries of 77 and FY19 deliveries of 665, assuming no 737 MAX deliveries until Q3, and sees the Paris Air Show as a potential pick up in order activity. Kahyaoglu has a Buy rating and $448 price target on Boeing shares.

TODAY'S FREE FLY STORIES

NOVA

Sunnova Energy

$11.13

0.089 (0.81%)

21:22
08/19/19
08/19
21:22
08/19/19
21:22
Initiation
Sunnova Energy initiated at KeyBanc »

Sunnova Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

SPY

SPDR S&P 500 ETF Trust

$292.31

3.52 (1.22%)

, SPX

S&P 500

$0.00

(0.00%)

20:54
08/19/19
08/19
20:54
08/19/19
20:54
Periodicals
Trump administration considering steps on economy if conditions worsen, NYT says »

White House officials…

SPY

SPDR S&P 500 ETF Trust

$292.31

3.52 (1.22%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSS

Kohl's

$48.20

2.69 (5.91%)

, TJX

TJX

$51.55

0.13 (0.25%)

20:25
08/19/19
08/19
20:25
08/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KSS

Kohl's

$48.20

2.69 (5.91%)

TJX

TJX

$51.55

0.13 (0.25%)

MDT

Medtronic

$104.15

1.42 (1.38%)

HD

Home Depot

$207.98

4.335 (2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 20

    Aug

  • 20

    Aug

  • 20

    Aug

  • 04

    Sep

  • 09

    Sep

BHP

BHP Group

$49.12

0.31 (0.64%)

19:32
08/19/19
08/19
19:32
08/19/19
19:32
Hot Stocks
BHP Group sees China and global economic growth slowing »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

BHP

BHP Group

$49.12

0.31 (0.64%)

19:25
08/19/19
08/19
19:25
08/19/19
19:25
Earnings
BHP Group reports FY19 Net profit up 124% at $8.31B »

Reports FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

AAPL

Apple

$210.32

3.88 (1.88%)

19:09
08/19/19
08/19
19:09
08/19/19
19:09
Periodicals
Apple aims for November launch of Apple+, Bloomberg reports »

Apple is targeting a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$195.19

2.005 (1.04%)

19:04
08/19/19
08/19
19:04
08/19/19
19:04
Hot Stocks
Accenture acquires Parker Fitzgerald, terms not disclosed »

Accenture has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Oct

BIDU

Baidu

$104.28

7.63 (7.89%)

, NBRV

Nabriva Therapeutics

$2.21

-0.06 (-2.64%)

18:47
08/19/19
08/19
18:47
08/19/19
18:47
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Baidu…

BIDU

Baidu

$104.28

7.63 (7.89%)

NBRV

Nabriva Therapeutics

$2.21

-0.06 (-2.64%)

MRNA

Moderna

$13.41

0.235 (1.78%)

VSLR

Vivint Solar

$8.30

0.3 (3.75%)

FN

Fabrinet

$56.40

0.77 (1.38%)

IQ

iQIYI

$18.10

1.02 (5.97%)

MRUS

Merus

$18.46

1.75 (10.47%)

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 04

    Sep

  • 09

    Sep

  • 12

    Sep

ET

Energy Transfer LP

$13.77

0.3 (2.23%)

18:40
08/19/19
08/19
18:40
08/19/19
18:40
Periodicals
Energy Transfer LP performing maintenance on WTG pipeline, Reuters says »

A spokeswoman for Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$210.32

3.88 (1.88%)

, SNE

Sony

$55.71

-0.01 (-0.02%)

18:20
08/19/19
08/19
18:20
08/19/19
18:20
Periodicals
Apple allocates over $6B for original TV shows and movies, FT says »

Apple (AAPL) has budgeted…

AAPL

Apple

$210.32

3.88 (1.88%)

SNE

Sony

$55.71

-0.01 (-0.02%)

NFLX

Netflix

$309.40

6.66 (2.20%)

DIS

Disney

$135.33

0.14 (0.10%)

T

AT&T

$35.40

0.42 (1.20%)

CBS

CBS

$44.21

0.38 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

LGIH

LGI Homes

$78.56

3.36 (4.47%)

18:01
08/19/19
08/19
18:01
08/19/19
18:01
Hot Stocks
LGI Homes opens two new communities in greater Seattle market »

LGI Homes announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

18:01
08/19/19
08/19
18:01
08/19/19
18:01
Hot Stocks
Amazon.com to expand in Utah with new new fulfillment center »

Amazon.com announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

WMT

Walmart

$113.76

0.77 (0.68%)

18:00
08/19/19
08/19
18:00
08/19/19
18:00
Hot Stocks
Walmart to pay $100,000 to settle EEOC disability discrimination suit »

Wal-Mart Stores East, LP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

X

U.S. Steel

$12.42

1.13 (10.01%)

17:58
08/19/19
08/19
17:58
08/19/19
17:58
Periodicals
U.S. Steel to lay off hundreds of workers at Great Lakes plant, Reuters says »

U.S. Steel plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

17:53
08/19/19
08/19
17:53
08/19/19
17:53
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta falls over 4% or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

17:52
08/19/19
08/19
17:52
08/19/19
17:52
Hot Stocks
FDA's CRL to Sarepta's golodirsen citing risk of infection, renal toxicity »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

BSX

Boston Scientific

$42.74

0.59 (1.40%)

17:41
08/19/19
08/19
17:41
08/19/19
17:41
Hot Stocks
Boston Scientific's ImageReady MRI labeling receives FDA approval »

Boston Scientific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 09

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

, GOOG

Alphabet

$1,198.01

21.07 (1.79%)

17:35
08/19/19
08/19
17:35
08/19/19
17:35
Periodicals
State AGs to proceed with antitrust investigation of big tech, WSJ reports »

A group of state…

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

GOOG

Alphabet

$1,198.01

21.07 (1.79%)

GOOGL

Alphabet Class A

$1,199.94

21.25 (1.80%)

FB

Facebook

$186.22

2.8 (1.53%)

MSFT

Microsoft

$138.43

2.3 (1.69%)

AAPL

Apple

$210.32

3.88 (1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

FB

Facebook

$186.22

2.8 (1.53%)

17:31
08/19/19
08/19
17:31
08/19/19
17:31
Periodicals
FTC head says breaking up Facebook could be complicated, FT reports »

Federal Trade Commission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

MPW

Medical Properties Trust

$18.28

0.13 (0.72%)

17:28
08/19/19
08/19
17:28
08/19/19
17:28
Hot Stocks
Medical Properties Trust COO sells 100K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

WMT

Walmart

$113.76

0.77 (0.68%)

17:17
08/19/19
08/19
17:17
08/19/19
17:17
Periodicals
Walmart's U.S. Chief Marketing Officer Barbara Messing is leaving, AdAge says »

Walmart U.S. Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

MAXR

Maxar Technologies

$6.49

0.185 (2.93%)

17:12
08/19/19
08/19
17:12
08/19/19
17:12
Hot Stocks
Maxar Technologies' MDA awarded Canadian Space Agency contract »

MDA, a Maxar company, has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCI

Rogers Communications

$51.30

0.21 (0.41%)

17:06
08/19/19
08/19
17:06
08/19/19
17:06
Hot Stocks
Rogers 'disappointed' by CRTC decision on broadband wholesale rates »

Rogers Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$18.10

1.02 (5.97%)

17:05
08/19/19
08/19
17:05
08/19/19
17:05
Hot Stocks
Breaking Hot Stocks news story on iQIYI »

iQIYI down over 6% or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

IQ

iQIYI

$18.10

1.02 (5.97%)

17:03
08/19/19
08/19
17:03
08/19/19
17:03
Hot Stocks
iQIYI reports Q2 total subscribing members 100.5M, up 50% from last year »

iQIYI's number of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.